Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment: original research article
Purpose - To analyze anatomic and functional response to intravitreal brolucizumab in age-related macular degeneration recalcitrant to previous intravitreal anti-VEGF therapies. - Methods - In this monocentric, one arm, retrospective study, eyes affected by neovascular age-related macular degenerati...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2024
|
| In: |
European journal of ophthalmology
Year: 2024, Jahrgang: 34, Heft: 2, Pages: 487-496 |
| ISSN: | 1724-6016 |
| DOI: | 10.1177/11206721231187663 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1177/11206721231187663 Verlag, lizenzpflichtig, Volltext: https://journals.sagepub.com/doi/10.1177/11206721231187663 
|
| Verfasserangaben: | Argyrios Chronopoulos, Elisa Huynh, Agharza Ashurov, James S Schutz, Jost B Jonas and Lars-Olof Hattenbach |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1881246264 | ||
| 003 | DE-627 | ||
| 005 | 20260205165852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/11206721231187663 |2 doi | |
| 035 | |a (DE-627)1881246264 | ||
| 035 | |a (DE-599)KXP1881246264 | ||
| 035 | |a (OCoLC)1425200644 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chronopoulos, Argyrios |d 1979- |e VerfasserIn |0 (DE-588)136184626 |0 (DE-627)577702262 |0 (DE-576)300882106 |4 aut | |
| 245 | 1 | 0 | |a Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment |b original research article |c Argyrios Chronopoulos, Elisa Huynh, Agharza Ashurov, James S Schutz, Jost B Jonas and Lars-Olof Hattenbach |
| 264 | 1 | |c 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 18. Juli 2023 | ||
| 500 | |a Gesehen am 20.02.2024 | ||
| 520 | |a Purpose - To analyze anatomic and functional response to intravitreal brolucizumab in age-related macular degeneration recalcitrant to previous intravitreal anti-VEGF therapies. - Methods - In this monocentric, one arm, retrospective study, eyes affected by neovascular age-related macular degeneration (nAMD) resistant to other intravitreally injected anti-vascular endothelial growth factor inhibitors were switched to intravitreal brolucizumab. All patients underwent ophthalmological examinations at baseline and in regular follow-up intervals. Best registered visual acuity (BRVA), Goldmann tonometry, intraocular pressure (IOP), central retinal thickness (CRT) and pigment epithelial detachment (PED) characteristics were analyzed at initiation of anti-VEGF treatment, at treatment switch, and at the end of brolucizumab loading phase. - Results - The study included 20 eyes of 18 consecutively treated patients (age: 77 ± 6 years). All eyes had macular neovascularization with PED. Previous treatments included intravitreal aflibercept, bevacizumab, and ranibizumab and had not resulted in a significant improvement in BRVA (0.5 ± 0.5 logMAR vs 0.5 ± 0.6 logMAR) or mean CRT (320 ± 60 µm vs 313 ± 83 µm) up to treatment switch to brolucizumab. At the end of the brolucizumab loading phase, there was significant improvement for both BRVA (0.3 ± 0.2 logMAR, P < 0.05) and CRT (264 ± 55 µm, P < 0.05). Under previous anti-VEGF therapy, there was a significant increase/deterioration in both PED area (2.68 mm2 to 5.18 mm2, P < 0.05) and PED volume (0.39 mm3 to 1.07 mm3, P < 0.05); however, both parameters improved after switching to brolucizumab (3.81 mm2 and 0.37 mm3, P < 0.05). - Conclusion - Our results suggest a favourable anatomical and visual response after treatment switch to brolucizumab in patients with nAMD refractory to previous anti-VEGF agents. | ||
| 700 | 1 | |a Huynh, Elisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ashurov, Agharza |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schutz, James S |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jonas, Jost B. |d 1958- |e VerfasserIn |0 (DE-588)1028286732 |0 (DE-627)730536823 |0 (DE-576)37578537X |4 aut | |
| 700 | 1 | |a Hattenbach, Lars-Olof |e VerfasserIn |0 (DE-588)1135612463 |0 (DE-627)890550832 |0 (DE-576)489878571 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of ophthalmology |d Thousand Oaks, CA : Sage Publishing, 1991 |g 34(2024), 2, Seite 487-496 |h Online-Ressource |w (DE-627)269534601 |w (DE-600)1475018-1 |w (DE-576)47295234X |x 1724-6016 |7 nnas |a Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment original research article |
| 773 | 1 | 8 | |g volume:34 |g year:2024 |g number:2 |g pages:487-496 |g extent:10 |a Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment original research article |
| 856 | 4 | 0 | |u https://doi.org/10.1177/11206721231187663 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://journals.sagepub.com/doi/10.1177/11206721231187663 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20240220 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1028286732 |a Jonas, Jost B. |m 1028286732:Jonas, Jost B. |d 60000 |e 60000PJ1028286732 |k 0/60000/ |p 5 | ||
| 998 | |g 136184626 |a Chronopoulos, Argyrios |m 136184626:Chronopoulos, Argyrios |d 60000 |e 60000PC136184626 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1881246264 |e 4488492800 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment","title_sort":"Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment","subtitle":"original research article"}],"origin":[{"dateIssuedDisp":"2024","dateIssuedKey":"2024"}],"note":["Online veröffentlicht: 18. Juli 2023","Gesehen am 20.02.2024"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"id":{"zdb":["1475018-1"],"issn":["1724-6016"],"eki":["269534601"]},"recId":"269534601","name":{"displayForm":["published in association with European Society of Ophthalomology (SOE), Italian Society of Ophthalmology (SOI), European Paediatric Ophthalmological Society (EPOS), European Association for the Study of Diabetes - Eye Complications Study Group (EASD)"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment original research articleEuropean journal of ophthalmology","type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Sage Publishing ; Wichtig","dateIssuedKey":"1991","dateIssuedDisp":"1991-","publisherPlace":"Thousand Oaks, CA ; Milano"}],"pubHistory":["1.1991 -"],"note":["Gesehen am 28.02.2020"],"title":[{"title":"European journal of ophthalmology","title_sort":"European journal of ophthalmology","subtitle":"EJO"}],"part":{"volume":"34","extent":"10","pages":"487-496","year":"2024","text":"34(2024), 2, Seite 487-496","issue":"2"},"titleAlt":[{"title":"EJO"}],"language":["eng"]}],"recId":"1881246264","physDesc":[{"extent":"10 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["Argyrios Chronopoulos, Elisa Huynh, Agharza Ashurov, James S Schutz, Jost B Jonas and Lars-Olof Hattenbach"]},"id":{"eki":["1881246264"],"doi":["10.1177/11206721231187663"]},"person":[{"family":"Chronopoulos","display":"Chronopoulos, Argyrios","given":"Argyrios","role":"aut"},{"role":"aut","given":"Elisa","display":"Huynh, Elisa","family":"Huynh"},{"family":"Ashurov","display":"Ashurov, Agharza","role":"aut","given":"Agharza"},{"family":"Schutz","display":"Schutz, James S","given":"James S","role":"aut"},{"role":"aut","given":"Jost B.","display":"Jonas, Jost B.","family":"Jonas"},{"role":"aut","given":"Lars-Olof","family":"Hattenbach","display":"Hattenbach, Lars-Olof"}],"language":["eng"]} | ||
| SRT | |a CHRONOPOULBROLUCIZUM2024 | ||